Doctors are testing a radical new way to help smokers quit: a shot that "immunizes" them against the nicotine rush that fuels their addiction.
That pleasurable buzz has seduced Mario Musachia into burning through nearly half a million cigarettes in half a century.
Now he is among 300 people around the country who are testing an experimental vaccine that makes the immune system attack nicotine in much the same way it would fight a life-threatening germ.
The treatment keeps nicotine from reaching the brain, making smoking less pleasurable and theoretically, easier to give up. The small amount that still manages to get in helps to ease withdrawal, the main reason most quitters relapse.
If it works -- and this has not yet been proved -- the vaccine could become part of a new generation of smoking cessation treatments. They attack dependency in the brain instead of just replacing the nicotine from cigarettes in a less harmful way, like the gum, lozenges, patches and nasal sprays sold today.
One such drug, Pfizer Inc's Chantix, is due on the market any day now. Another, Sanofi-Aventis SA's Acomplia, recently won approval in Europe as a weight-loss drug. If US regulators follow suit, some doctors say they also will use it to help smokers quit, especially those concerned about gaining weight.
"The typical patient is a 30-year-old woman who says, `If I gain five pounds, I'm going back,'" said J. Taylor Hays, a smoking cessation expert at the Mayo Clinic in Rochester, Minnesota, who helped test Chantix and other treatments.
Other novel drugs are in development, but NicVax, by Nabi Biopharmaceuticals, a Florida-based biotechnology company, is the most advanced among the vaccines.
After four smaller studies suggested it might be safe and effective, the new, larger study was started in Madison, Wisconsin; Minneapolis; Omaha, Nebraska; San Francisco; Los Angeles; Boston and New York City.
The Food and Drug Administration has granted the vaccine fast-track status, meaning it will get prompt review, and the National Institute on Drug Abuse just gave Nabi a second US$4 million grant to finance the study and NicVax's development.
"It's going to be a very good way to keep people from relapsing," predicts Frank Vocci, director of medications development at the federal institute.
Relapse is the biggest problem quitters face.
Of the more than 48 million smokers in the US, 40 percent each year make a serious attempt to quit, but fewer than 5 percent succeed long-term. Nicotine replacement products combined with counseling can double that rate, but most quitters do not try them. Two-thirds go back to smoking within a month.
"When they have that first cigarette, if they really enjoy it, they're at high risk of relapse. If you can make that cigarette not so good, you've really got something," Vocci said.
The possibility that a simple shot could do this is what lured Musachia to the Center for Tobacco Research and Intervention on the fringes of the University of Wisconsin-Madison campus earlier this month. He has tried many ways to quit but still smokes.
"I'm sick of it. I'm surprised I've lived this long," said the 75-year-old man. "My kids -- they carry on like two-year-olds when I smoke around them. My animals run and hide."
He and other participants will get four or five shots, either four or six weeks apart, and will be studied for a year. Two-thirds will get the vaccine; the others, dummy shots. Neither they nor the doctors will know who got what until the study ends.
They also will get counseling and must set a quit date, usually around the second shot, because the first shot is just meant to "prime" the immune system. Subsequent doses make the immune system produce antibodies, which latch onto nicotine in the bloodstream and keep it from crossing the blood-brain barrier and getting into the brain where it maintains the addiction.
"They won't get the rush, the reward," but the small amount still getting in "we think is an advantage," because it should lessen withdrawal symptoms, said Henrik Rasmussen, Nabi's chief medical officer.
The antibodies should remain in the system for up to a year; booster shots may be needed after that, but this needs more study, Rasmussen said.
As the sun sets on another scorching Yangon day, the hot and bothered descend on the Myanmar city’s parks, the coolest place to spend an evening during yet another power blackout. A wave of exceptionally hot weather has blasted Southeast Asia this week, sending the mercury to 45°C and prompting thousands of schools to suspend in-person classes. Even before the chaos and conflict unleashed by the military’s 2021 coup, Myanmar’s creaky and outdated electricity grid struggled to keep fans whirling and air conditioners humming during the hot season. Now, infrastructure attacks and dwindling offshore gas reserves mean those who cannot afford expensive diesel
Does Argentine President Javier Milei communicate with a ghost dog whose death he refuses to accept? Forced to respond to questions about his mental health, the president’s office has lashed out at “disrespectful” speculation. Twice this week, presidential spokesman Manuel Adorni was asked about Milei’s English Mastiff, Conan, said to have died seven years ago. Milei, 53, had Conan cloned, and today is believed to own four copies he refers to as “four-legged children.” Or is it five? In an interview with CNN this month, Milei referred to his five dogs, whose faces and names he had engraved on the presidential baton. Conan,
French singer Kendji Girac, who was seriously injured by a gunshot this week, wanted to “fake” his suicide to scare his partner who was threatening to leave him, prosecutors said on Thursday. The 27-year-old former winner of France’s version of The Voice was found wounded after police were called to a traveler camp in Biscarrosse on France’s southwestern coast. Girac told first responders he had accidentally shot himself while tinkering with a Colt .45 automatic pistol he had bought at a junk shop, a source said. On Thursday, regional prosecutor Olivier Janson said, citing the singer, that he wanted to “fake” his suicide
Indian Prime Minister Narendra Modi reaffirmed his pledge to replace India’s religion-based marriage and inheritance laws with a uniform civil code if he returns to office for a third term, a move that some minority groups have opposed. In an interview with the Times of India listing his agenda, Modi said his government would push for making the code a reality. “It is clear that separate laws for communities are detrimental to the health of society,” he said in the interview published yesterday. “We cannot be a nation where one community is progressing with the support of the Constitution while the other